AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Biotech firms use AI in trials to target patients more ...
OpenAI is bringing in about $20 billion less in annualized revenue than investors had been led to believe, the Financial Times reported Thursday, raising questions about the solidity of the AI ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. "People think pattern recognition is about predicting ...
I reiterate a Hold rating on State Street SPDR S&P Biotech ETF due to fair valuation and mixed technicals. XBI's recent outperformance has faded, with higher interest rates and a less risk-on market ...
In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results